Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1 H -1,4-benzodiazepin-3-yl]-3-(3-methylaminophenyl)urea

EU orphan designation number: EU/3/07/452   
Active ingredient: R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1 H -1,4-benzodiazepin-3-yl]-3-(3-methylaminophenyl)urea
Indication: Treatment of gastric carcinoid
Sponsor: Trio Medicines Ltd
Hammersmith Medicines Research, Cumberland Avenue, London NW10 7EW, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page
Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
19/06/2007 Orphan designation EMEA/OD/014/07 (2007)3028 of 14/06/2007
31/07/2015 Change of name and/or address of sponsor